Background: Sex differences have been reported in the incidence, prevalence and severity of asthma. Previous findings from animal models have revealed sex-related differences in inflammatory pathways that may contribute to asthma pathogenesis, but human studies are limited.
Methods: Airway and blood samples (n = 55 and n = 85 respectively) were collected from adult females and males with asthma and healthy subjects. Type 2 innate lymphoid cells (ILC2s), T helper (Th)2 cells and their expression of IL-33R/ST2 (ST2L) were evaluated by flow cytometry. IL-13, thymic stromal lymphopoietin (TSLP), IL-33 and soluble IL-33R/ST2 (sST2) were measured by ELISA. Let-7 miRNA expression in bronchial biopsies was determined by qPCR.
Results: Females with asthma reported more exacerbations and had a higher number of airway eosinophils compared with males with asthma. Bronchial biopsy expression of Let-7f, Let-7g and miR-98 tended to be higher in males with asthma compared with females and inversely correlated with asthma exacerbations. In contrast, increased levels of IL-13, TSLP and sST2 were found in females with asthma compared with males.
Conclusion: Our study demonstrates different inflammatory signatures between males and females with asthma. Let-7 miRNAs act as immune modulators by inhibiting the production of IL-13 and may be an important factor explaining the sex disparity seen in asthma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871111 | PMC |
http://dx.doi.org/10.1002/clt2.70042 | DOI Listing |
JAMA Psychiatry
March 2025
Center for Neuropsychiatric Schizophrenia Research (CNSR& Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, Copenhagen University Hospital - Mental Health Services CPH, Copenhagen, Denmark.
Importance: Maternal inflammation during pregnancy has been associated with an increased risk of neurodevelopmental disorders (NDDs), such as attention-deficit/hyperactivity disorder (ADHD) and autism, and cognitive deficits in early childhood. However, little is known about the contributions of a wider range of inflammatory proteins to this risk.
Objective: To determine whether maternal inflammatory proteins during pregnancy are associated with the risk of NDDs and executive functions (EF) in middle childhood and to identify protein patterns associated with NDDs and EF.
Pediatr Pulmonol
March 2025
Asthma UK Centre for Applied Research, USHER Institute, University of Edinburgh, Edinburgh, UK.
Background And Aim: Children and young people (CYP) with severe, sub-optimally controlled asthma and co-existing allergic senitization to indoor aeroallergens, such as pet dander and house dust mite (HDM), would likely benefit from reduced allergen exposure. Multiple allergen remediation interventions exist and are often suggested to families in secondary care asthma clinics in the United Kingdom. Evidence suggests remediation uptake is low or partial but there is sparse evidence to explain why.
View Article and Find Full Text PDFTher Adv Respir Dis
March 2025
Pediatric Department, Medisch Spectrum Twente, Enschede, The Netherlands.
Background: Asthma is one of childhood's most prevalent chronic conditions significantly impacting the quality of life. Current asthma management lacks real-time, objective, and longitudinal monitoring reflected by a high prevalence of uncontrolled asthma. Long-term home monitoring promises to establish new clinical endpoints for timely anticipation.
View Article and Find Full Text PDFIndian J Otolaryngol Head Neck Surg
January 2025
Otorhinolaryngology Department, Faculty of Medicine, Benha University, Benha, Qalyubia Egypt.
SARS-CoV-2 infection may lead to olfactory dysfunctions affecting patients' quality of life. Despite various ongoing studies, solid evidence supporting therapies, especially for COVID-19-related olfactory dysfunction, remains scarce. To assess nasal steroid, nasal vitamin A, and intranasal theophylline as treatment options for post-COVID-19 olfactory dysfunction.
View Article and Find Full Text PDFLung
March 2025
Department of Respiratory Medicine, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark.
Background: In severe asthma, intensive ("supratherapeutic") doses of inhaled corticosteroids (ICS) are often used. The prevalence of supratherapeutic ICS use and its impact on corticosteroid-related comorbidities is poorly understood. We aimed to describe the prevalence of supratherapeutic ICS use in severe asthma, its relation to corticosteroid-related comorbidities, and changes in prescribed and redeemed ICS dose after 12 months of biologic therapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!